Kate Worthington, PhD MBA

Kate Worthington, PhD MBA has extensive work experience in the pharmaceutical and biotechnology industry. Kate has held various roles in companies such as Rapid Commercialization Partners, Next Phase Biotech, Kura Oncology, and Sage Therapeutics.

At Rapid Commercialization Partners, Kate serves as the Chief Operating Officer, providing COO support and guidance to biotech clients in pre-commercialization activities.

At Next Phase Biotech, they have worked as a Principal, leading discussions with executives on pre-launch plans and assisting EU companies in establishing a presence in the US. Kate has also served as an Interim Vice President of Medical Affairs, where they defined and built the Medical Affairs function and developed strategies for clinical studies. Additionally, they have served as an Interim Chief Operations Officer for a clinical-stage oncology startup, advising the management team on go/no-go decisions and establishing partnerships with regulatory agencies.

As a Senior Medical Director, Kate has worked as a consultant for companies such as TESARO Inc and ARIAD Pharmaceuticals. In these roles, they have developed medical affairs plans, managed the publication process, and trained teams on compliance and promotional review.

Kate has also held positions at Celldex Therapeutics, where they served as a Senior Director of Medical Affairs, leading the establishment of the Medical Affairs group and supporting commercial activities. Kate has also worked as a Medical Director at Sanofi and Merck, and as the Medical Director and Consultant at The Ben and Catherine Ivy Foundation.

Earlier in their career, Kate worked in licensing and business development at EMD Serono and as an Analyst in the Commercialization Group at Research Corporation Technologies. In these roles, they conducted market research, analyzed potential investments, and initiated partnerships.

Overall, Kate Worthington's work experience showcases their expertise in various areas of the pharmaceutical and biotechnology industry, including medical affairs, operations, and commercialization. Kate'sexperience encompasses responsibilities such as strategic planning, team management, and regulatory compliance.

Kate Worthington, PhD MBA, has an extensive education history spanning multiple institutions and fields of study. Kate received their PhD in Tumor Cell Biology from Northwestern University in 1994. Prior to that, Worthington completed their undergraduate studies in Biology at Syracuse University, earning a BS degree in 1988. Kate also spent a year at Cornell University studying Mechanical Engineering in 1983.

In terms of business education, Worthington obtained an MBA with a focus on Organizational Behavior from Syracuse University's Martin J. Whitman School of Management in 1998. Furthermore, they pursued additional professional development at the Harvard T.H. Chan School of Public Health, where they completed a program called "Women on Boards: Getting On and Adding Value" in 2018.

Worthington's education journey began at The Fay School, where they completed their middle school education from 1978 to 1980. Kate then attended Kent School and graduated with a High School diploma in 1983.

Based on the provided information, it can be concluded that Kate Worthington's education demonstrates a blend of scientific expertise in Tumor Cell Biology and business knowledge in Organizational Behavior, with an additional focus on women's representation on corporate boards.